October 4-5, 2021 Webconference

The Longwood Healthcare Leaders meeting, centered on Cambridge/Boston via webconference, October 4-5, 2021, brings together leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors for an off-the-record forum focused on accelerating the translation of discoveries into medicines to help patients.

Speakers include FDA Commissioner Janet Woodcock, MA Governor Charlie Baker, Takeda CEO Christophe Weber, Regeneron President & CSO George Yancopoulos, Janssen Pharmaceuticals global commercial strategy chair Vanessa Broadhurst, GSK CSO & head of R&D Hal Barron, AbbVie Chief Strategy Officer Henry Gosebruch, Bayer Pharmaceuticals CEO Stefan Oelrich, Broad Institute Senior Fellow Mary Lynne Hedley, Biogen head of R&D Al Sandrock, BMS Research & Early Development head Rupert Vessey, Sanofi global research head & CSO Frank Nestle, Janssen Global Head of R&D Mathai Mammen, Eisai Chief Clinical Officer Lynn Kramer, Moderna co-founder Bob Langer, Amgen R&D head Dave Reese, Gilead CMO Merdad Parsey, among others.

These meetings are off-the-record and focused on accelerating the translation of discoveries into medicines to help patients; substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities.

LONGWOOD HEALTHCARE LEADERS | AGENDA | OCTOBER 4 - 5, 2021

 – all times Eastern Standard –

 

MONDAY, OCTOBER 4, 2021 | AGENDA

 

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION

Christoph Westphal, General Partner, Longwood Fund; David Steinberg, General Partner, Longwood Fund

7:30 – 8:00 | NEWCO TO ESTABLISHED: BUILDING A BIOTECH
PJ Anand, CEO, Alcyone; Philip Astley-Sparke, CEO, Replimune; Jeff Goldberg, CEO, Immunitas; Jim Scibetta, CEO, ImmuneID

Moderator: Chad Shear, Principal, Fish & Richardson 

 

8:00 – 8:30 | R&D COLLABORATION
Steve Hitchcock, Head, Research, Takeda; Philip Larsen, Global Head, Research & Early Development, Bayer Pharmaceuticals; Raquel Mura, Head, R&D, North America, Sanofi; Tarek Samad, SVP & Global Head, Research, Lundbeck; Rupert Vessey, President, Research & Early Development, Bristol Myers Squibb

Moderator: John Westwood, Managing Director, Huron

 

8:30 – 8:50 | FIRESIDE CHAT

Marc Casper, CEO, Thermo Fisher Scientific; Stefan Oelrich, CEO, Bayer Pharmaceuticals

Moderator: Christoph Westphal, General Partner, Longwood Fund

 

8:50 – 9:20 | SPOTLIGHT ON INNOVATION
Galit Alter, Co-Director, Center for AIDS Research, Harvard University; Paola Arlotta, Professor and Chair, Stem Cell and Regenerative Biology, Harvard University; George Church, Professor, Harvard Medical School; David Walt, Professor, Biologically Inspired Engineering, Harvard Medical School; Kai Wucherpfennig, Professor, Neurology, Harvard Medical School, Scientific Co-Founder, Immunitas

Moderator: David Sinclair, Co-Director, Center for Biology of Aging Research, Harvard Medical School

 

9:20 – 9:50 | HOW M&A SPURS INNOVATION 
Juergen Eckhardt, Head, Leaps, Bayer; Ivana Magovcevic-Liebisch, CEO, Vigil Neuroscience; Chen Schor, CEO, Adicet Bio

Moderator: Diana Gallagher, Head, External Innovation & New Indications, Biogen

 

9:50 – 10:20 | EXPEDITING RESEARCH FOR TREATMENTS AND CURES
John Connolly, CSO, Parker Institute; Daria Donati, Head, BD & Strategic Technology Partnerships, Cytiva; Lynn Kramer, Chief Clinical Officer, Eisai; Brad Margus, CEO, Cerevance; Laura Sepp-Lorenzino, CSO, Intellia

Moderator: Ed Kaye, CEO, Stoke Therapeutics

 

10:20 – 10:40 | FIRESIDE CHAT
George Scangos, CEO, Vir Bio; Christophe Weber, CEO, Takeda

Moderator: Christoph Westphal, General Partner, Longwood Fund


10:40 – 11:10 | SOURCING AND IDENTIFYING NOVEL TECHNOLOGY
Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie; Jak Knowles, CEO, Affini-T Therapeutics; Reenie McCarthy, CEO, Stealth BioTherapeutics; Karen Nelson, CSO, Thermo Fisher Scientific

Moderator: Michal Preminger, Regional Head, Johnson & Johnson Innovation, East North America

 

11:10 – 11:40 | PUBLIC-PRIVATE PARTNERSHIPS
PJ Brooks, Program Director, Rare Diseases, NIH; Jonathan Javitt, CEO, NRx; Bill Mezzanotte, EVP, Head R&D & CMO, CSL Behring; Iskra Reic, EVP, Europe & Canada, AstraZeneca; Courtney Silverthorn, AVP, Research Partnerships, Foundation for the NIH

Moderator: Art Krieg, CSO, Checkmate Pharmaceuticals

 

11:40 – 12:00 | REGULATORY KEYNOTE
Peggy Hamburg, former Commissioner, FDA; Janet Woodcock, Acting Commissioner, FDA

Moderator: Christoph Westphal, General Partner, Longwood Fund

 

12:00 – 12:30 | CREATING A WORLD WITHOUT DISEASE
Ivan Cheung, US Chair, Global President, Neurology, Eisai; Mike Devoy, CMO, Bayer; Reed Jobs, Managing Director, Health, Emerson Collective; Sandy Macrae, CEO, Sangamo

Moderator: Bill Hait, Global Head, External Innovation, Johnson & Johnson Innovation

 

12:30 – 1:00 | GLOBAL MARKETS: WORKING ACROSS BORDERS
Hafrun Fridriksdottir, EVP, Global R&D, Teva; Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Digital Marketing, Merck; Ken Keller, CEO, Global Head, Oncology, Daiichi Sankyo Inc.; Paul Perreault, CEO, CSL Limited

Moderator: Philippe Lopes-Fernandes, CBO, Ipsen

 

1:00 – 1:30 | ADVANCING PLATFORM TECHNOLOGIES

Aoife Brennan, CEO, Synlogic; Christina Coughlin, CMO, Rubius Therapeutics; Pearl Huang¸ CEO, Cygnal Therapeutics; Chad May, SVP, R&D, Takeda; Alise Reicin, CEO, Tectonic

Moderator: Annalisa D’Andrea, President & CSO, ImmuneID

 

1:30 – 1:50 | FIRESIDE CHAT
Hal Barron,
CSO & President, R&D, GlaxoSmithKline; Mathai Mammen, Global Head, R&D, Janssen Pharmaceuticals

Moderator: Christoph Westphal, General Partner, Longwood Fund

1:50 – 2:20 | PREPARING FOR THE FUTURE OF R&D
Ray Deshaies, SVP, Global Research, Amgen; Ruxandra Draghia-Akli, Global Head, Global Public Health R&D, Janssen; Anne Heatherington, Head, Data Sciences Institute, Takeda; Frank Nestle, Global Head of Research & CSO, Sanofi

Moderator: Luigi Gentile, CRO, BenchSci

 

2:20 – 2:50 | DESIGNING THE DEAL
Stacy Coen,
CBO, ImmunoGen; Alban de La Sabliere, SVP, Global Head, Partnering, Sanofi; Nouhad Husseini, SVP, Head, BD, Regeneron; Matthias Muellenbeck, SVP, Head Global BD & Alliance Management, EMD Serono; Patrick Verheyen, Global Head, BD, Janssen

Moderator: Tim Shannon, General Partner, Canaan

 

2:50 – 3:20 | INNOVATION IN CELL THERAPY
Diana Brainard, CEO, AlloVir; Paul Lammers, CEO, Triumvira; Armon Sharei, CEO, SQZ Biotech; Joanne Smith-Farrell, CEO, Be Biopharma; Pascal Touchon, CEO, Atara

Moderator: Maria Whitman, Head, Pharma, ZS Associates

 

3:20 – 3:40 | FIRESIDE CHAT
John Reed, EVP, Global Head, R&D, Sanofi; Al Sandrock, Head, R&D, Biogen

Moderator: David Steinberg, General Partner, Longwood Fund

3:40 – 4:10 | MAKING A BIG IMPACT WITH LIMITED RESOURCES

Manuel Aivado, CEO, Aileron Therapeutics; Greg Fiore, CEO, Exacis Biotherapeutics; Adelene Perkins, CEO, Infinity Pharmaceuticals; Alice Pomponio, Managing Director, BrightEdge, American Cancer Society; Roger Tung, CEO, Concert Pharmaceuticals

Moderator: Al Beardsley, COO, Galera

4:10 – 4:40 | ACCELERATING DRUG DEVELOPMENT
Jennifer Buell, President & COO, Agenus; Paulo Fontoura, Global Head & SVP, Rare Diseases, Roche; Al Gianchetti, CEO, XyloCor; Sean McClain, CEO, Absci; Aaron Mitchell, R&D Excellence Practice Lead, ZS Associates

Moderator: JC Gutierrez-Ramos, CSO, Danaher Corporation

 

4:40 – 5:10 | NOVEL APPROACHES TO DRUG DISCOVERY

Stewart Campbell, CEO, Axial Therapeutics; Fabrice Chouraqui, CEO, Cellarity; Chris Gibson, CEO, Recursion Pharma; Zach Hornby, CEO, Boundless Bio; Gavin MacBeath, CSO, TScan Therapeutics

Moderator: Bobby Azamian, CEO, Tarsus

5:10 – 5:40 | MAKING SMART INVESTMENTS
Sarah Bhagat, General Partner, Sofinnova; Ansbert Gadicke, Managing Director, MPM Capital; Arjun Goyal, Managing Director, Vida Ventures; Dan Omstead, CEO, Tekla Capital Management

Moderator: Priyanka Rohatgi, Venture Partner, Longwood Fund

 

5:40 – 6:00 | LONGWOOD FUND SUMMARY

Priyanka Rohatgi, Venture Partner, Longwood Fund

 

TUESDAY, OCTOBER 5, 2021

 

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION

Christoph Westphal, General Partner, Longwood Fund; David Steinberg, General Partner, Longwood Fund

 

7:30 – 8:00 | HARNESSING BIOMEDICAL INNOVATION
Shannon Dahl, former CSO, Cell Care Therapeutics; Sekar Kathiresan, CEO, Verve Therapeutics; Denitsa Milanova, CEO, Marble Therapeutics; David Southwell, CEO, TScan Therapeutics

Moderator: Chandra Ramanathan, Global Head, Pharma R&D, Open Innovation, Bayer

 

8:00 – 8:30 | MODERATED KEYNOTE

Charlie Baker, Governor, Massachusetts

Moderator: Christoph Westphal, General Partner, Longwood Fund


8:30 – 8:50 | HEALTH SYSTEMS IN A NEW ERA

Laurie Glimcher, CEO, Dana-Farber Cancer Institute; Tom Sequist, Chief Patient Experience & Equity Officer, Mass General Brigham

Moderator: David Steinberg, General Partner, Longwood Fund

 

8:50 – 9:20 | BIG BIOPHARMA R&D
Kathy Fernando,
Head, Operations, WW Research Development & Medical Operations, Pfizer; Larry Hamann, Global Head, Drug Discovery Sciences, Takeda Pharmaceuticals; Jim List, Global Therapeutic Head Cardiovascular, Metabolism, & Retina, Janssen; Christian Rommel, EVP, Head, R&D, Bayer Pharmaceuticals

Moderator: Levi Garraway, EVP, Head of Global Product Development & CMO, Genentech


9:20 – 9:50 | ACCELERATING THE PATH TO PATIENT CARE
Fred Hassan, former Chair & CEO, Pharmacia, Schering-Plough; Kabir Nath, CEO, Otsuka US; Ryan Richardson, Chief Strategy Officer, BioNTech; Melinda Richter, Head, JLabs, Johnson & Johnson Innovation; David Weinreich, EVP, Head, Global Clinical Development, Regeneron

Moderator: Colin Hill, CEO, GNS Healthcare

9:50 – 10:20 | DEVELOPING A WORLD-CLASS BOARD
Bill Heiden, Chair, Third Pole Therapeutics; Arlene Morris, Director, Cogent Biosciences; Catherine Sohn, Chair, BioEclipse Therapeutics; Shehnaaz Suliman, Chair, Board Room Ready, Women in Bio

Moderator: Julie Kampf, CEO, JBK Associates International

 

10:20 – 10:40 | FIRESIDE CHAT
David Loew, CEO¸ IPSEN; Paul Perreault, CEO, CSL Limited

Moderator: David Steinberg, General Partner, Longwood Fund


10:40 – 11:10 | SCIENTIFIC INNOVATION: LAUNCHING COMPANIES FROM ACADEMIA
Jessica Grossman, CEO, IgGenix; Juliette Han, COO, Cambrian Bio; Richard James, Principal Investigator, Seattle Children's Research Institute; Phil Johnson, CEO, Interius BioTherapeutics; Lloyd Minor, Dean, Stanford School of Medicine

Moderator: Joel Marcus, Executive Chairman & Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

11:10 – 11:40 | CLINICAL TRIAL EFFICIENCY

Derk Arts, CEO, Castor;  Everett Crosland, Chief Commercial Officer, Cognito Therapeutics; Steve Potts, CEO, OncoMyx Therapeutics; John Renger, CSO, Cerevel Therapeutics

Moderator: Bill Hinshaw, CEO, Axcella Health

 

11:40 – 12:10 | PERSISTENCE: THE LONG ROAD TO DRUG APPROVAL

Steve Kanes, CMO, Sage Therapeutics; Stuart Peltz, CEO, PTC Bio; Zhen Su, CEO, Marengo Therapeutics

Moderator: Oliver Rosen, CMO, SQZ Biotech

 

12:10 – 12:30 | FIRESIDE CHAT

Vanessa Broadhurst, Company Group Chairman, Global Commercial Strategy, Janssen Pharmaceuticals; Henry Gosebruch, Chief Strategy Officer, AbbVie

Moderator: David Steinberg, General Partner, Longwood Fund

12:30 – 1:00 | INNOVATIVE PARTNERSHIPS

Bram Goorden, COO, SOPHiA GENETICS; Jason Kelly, CEO, Ginkgo Bioworks; Jeremy Levin, CEO, Ovid Therapeutics; Kendra Rose, VP & Head, New Business Development, Bayer

Moderator: Bob Silverman, CBO, Rejuveron

 

1:00 – 1:30 | ACTIONABLE DIVERSITY, EQUITY, AND INCLUSION
Kristen Hege, SVP, Early Clinical Development, Bristol Myers Squibb; Quita Highsmith, Chief Diversity Officer, Genentech; Frank Lee, CEO, Forma Therapeutics

Moderator: Maria Rivas, CMO, EMD Serono

 

1:30 – 2:00 | NOVEL THERAPEUTIC MODALITIES

Liz Buck, CSO, Black Diamond Therapeutics; Brett Monia, CEO, Ionis; Rick Morgan, CSO, Be Biopharma; Anabella Villalobos, SVP, Biotherapeutics & Medicinal Sciences, Biogen; Ottavio Vitolo, CMO, Alcyone

Moderator: Brian McVeigh, CEO, Code Bio

 

2:00 – 2:20 | FIRESIDE CHAT
Mikael Dolsten, CSO & President, Worldwide Research, Development and Medical, Pfizer; Bob Langer, Co-Founder, Moderna/Momenta, NAS; Phil Sharp, Co-Founder, Biogen/Alnylam

Moderator: David Steinberg, General Partner, Longwood Fund

2:20 – 2:50 | EVOLVING BUSINESS STRATEGIES: THE SPIN OUT
Kevin Ali, CEO, Organon; Errik Anderson, CEO, Alloy Therapeutics; Myrtle Potter, CEO, Sumitovant

Moderator: Adam Bruce, Founder & Boardmember, TikoMed

 

2:50 – 3:20 | FROM DATA TO MEDICINE
Christopher Fang, Head of Global Medical Affairs Office, Eli Lilly; Kevin Fitzgerald, CSO, Alnylam; Najat Khan, Chief Data Science Officer, Global Head, R&D Strategy & Operations, Janssen; Michael Mina, Asst. Professor, Epidemiology, Harvard School of Public Health; Lihua Yu, Chief Data Officer, Fog Pharma

Moderator: Paul Schimmel, Professor, Cell & Molecular Biology, Scripps

 

3:20 – 3:40 | FIRESIDE CHAT

Merdad Parsey, EVP & CMO, Gilead; David Reese, EVP, R&D, Amgen; George Yancopoulos, President & CSO, Regeneron

Moderator: Christoph Westphal, General Partner, Longwood Fund

3:40 – 4:10 | INCORPORATING NOVEL DIAGNOSTIC APPROACHES

Alex Aravanis, CTO, Head of Research and Product Development, Illumina; Paul Billings, CMO, Natera; Priti Hegde, CSO, Foundation Medicine; John McAuliffe, Head, CDx Partnering, Roche Diagnostics; Gang Song, Founder and Chairman, Pillar Biosciences

Moderator: Gerald Commissiong, CEO, Todos Medical

 

4:10 – 4:40 | APPROACHES TO REGULATORY HURDLES

Dietmar Berger, CMO, Global Head of Development, Sanofi; Peter Hutt, former General Counsel, FDA; Thomas Lonngren, former Executive Director, EMA; Niels Riedemann, CEO, InflaRx; Raymond Sanchez, CMO, Cerevel Therapeutics

Moderator: Todd Krueger, CEO, AOBiome

 

4:40 – 5:00 | LONGWOOD FUND UPDATE

Aleks Radovic-Moreno, Partner, Longwood Fund

5:00 – 5:30 | EXTERNAL INNOVATION
Henry Gosebruch, Chief Strategy Officer, AbbVie; Mary Lynne Hedley, Senior Fellow, Broad Institute, MIT; Sridaran Natesan, Head, Strategic Initiatives & Science Relations, Sanofi; Chris Viehbacher, Managing Partner, Gurnet Point Capital

Moderator: Nenad Grmusa, Head, Center for External Innovation, Takeda

 

5:30 – 6:00 | PREDICTING SUCCESSFUL INVESTMENTS
Lucio Iannone, VP, Venture Investments, Bayer; Steve Kafka, Managing Partner, Section 32; Judith Li, Partner, Lilly Asia Ventures;

Rene Mora, Portfolio Manager, Monashee Investment Management; Aleks Radovic-Moreno, Partner, Longwood Fund

Moderator: Kyle Lefkoff, General Partner, Boulder Ventures

Supporters

We are grateful to the following organizations for their support of this meeting. To learn more about getting involved contact susan@longwoodfund.com

ARE_RGB_Stacked_Tagline_300dpi.jpg
Logo2020_Transparent_RGB.png

BenchSci's vision is to help scientists bring novel medicine to patients 50% faster by 2025. We do this by empowering scientists to run more successful experiments with the world's most advanced, intuitive biomedical artificial intelligence software platform, thereby avoiding delays that slow the progress of medicine to clinical trials. BenchSci is an indispensable tool for more than 41,000 scientists that accelerates research at 15 top 20 pharmaceutical companies and over 4,300 leading academic centers. For more information, visit: www.benchsci.com

Cytiva

Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.

FR13007-logo_RGB_300dpi_FINAL.jpg

Fish & Richardson, a premier global intellectual property (IP) law firm, works with pioneering life sciences companies to help them achieve their strategic IP goals through partnering, licensing, financing, acquisition, and enforcement. We do this by bringing a unique, holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP. For more information, visit: www.fr.com

GNS_Healthcare_logo_edited.jpg

GNS Healthcare is an AI company developing Gemini — The in silico Patient™ models from clinico-genomic data across oncology, auto-immune diseases, and neurology. In silico patients allow for clinical trials across cohorts of diverse patients to be conducted computationally by simulating disease progression and drug response at the individual patient level. GNS’ REFS causal AI and simulation technology integrates and transforms a wide-variety of multi-omic and real-world data to reveal the complex system of interactions underlying disease progression — constructing in silico patients. GNS partners with the world’s leading biopharmaceutical companies and health plans and has validated its science and technology in more than 60 publications and abstracts. For more information, visit: www.gnshealthcare.com

huron logo.JPG

Biopharmaceutical and medical device companies remain under pressure to navigate ever-changing environments. We work with our clients to innovate and improve health outcomes while justifying product value. Huron’s life sciences business is part of Huron’s continuum of healthcare offerings supporting the development and commercialization of technologies in these companies.

 

Discover how Huron can help you to harness new developments and stay ahead of the curve.

•             Corporate and Franchise Strategy

•             Commercial Strategy

•             R&D Strategy

•             Business Development Strategy

•             Market Access and Pricing

For more information, visit: www.huronconsultinggroup.com

JBK.png

JBK Associates International is a woman-owned, global executive search firm that is a leader in the recruitment and retention of diverse talent across a wide spectrum of industries with exceptional depth in the Life Sciences. Our D&I expertise spans 19 years and supports our client's strategy for creating the most inclusive organizations with the greatest ROI.  We bring great leaders to great companies. For more information, visit: www.jbkassociates.net

Jefferies_Logo_Black_300dpi (2).jpg

Jefferies Group LLC is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly-owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company. For more information, visit: www.jefferies.com

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. For more information, visit www.takeda.com

BrandSymbol_Dakiyama_white outline_Red (1).gif
Thermo Fisher Scientific.jpg

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, visit www.thermofisher.com

zs_logo_RGB.jpg

ZS is a global professional services firm that leverages deep industry expertise, leading-edge analytics, technology and strategy to create solutions for clients that work in the real world. For more information, visit www.zs.com